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A disordered to β-sheet transition was thought to drive the functional switch of Q/N-rich
prions, similar to pathogenic amyloids. However, recent evidence indicates a critical role for
coiled-coil (CC) regions within yeast prion domains in amyloid formation. We show that
many human prion-like domains (PrLDs) contain CC regions that overlap with polyQ tracts.
Most of the proteins bearing these domains are transcriptional coactivators, including the
Mediator complex subunit 15 (MED15) involved in bridging enhancers and promoters. We
demonstrate that the human MED15-PrLD forms homodimers in solution sustained by CC
interactions and that it is this CC fold that mediates the transition towards a β-sheet amyloid
state, its chemical or genetic disruption abolishing aggregation. As in functional yeast prions,
a GFP globular domain adjacent to MED15-PrLD retains its structural integrity in the amyloid
state. Expression of MED15-PrLD in human cells promotes the formation of cytoplasmic and
perinuclear inclusions, kidnapping endogenous full-length MED15 to these aggregates in a
prion-like manner. The prion-like properties of MED15 are conserved, suggesting novel
mechanisms for the function and malfunction of this transcription coactivator.
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Prions were first described as protein-only infectious agentsin the context of mammalian neurological disorders1.Nevertheless, increasing evidence indicates that prion-like
conformational conversion is not always deleterious; instead, it
can be exploited for beneficial purposes2. The best characterized
nonpathogenic prions are those of yeast, where they provide
increased fitness in fluctuating environments3,4, mainly by reg-
ulating transcription and translation5. Yeast prions are modular
proteins, and their conformational promiscuity is encoded at
their prion domains (PrDs), which are both sufficient and
necessary for prion conversion6. PrDs are long and disordered
sequences of low complexity, often enriched in glutamine and/or
asparagine (Q/N) residues. Polypeptides containing similar Q/N-
rich prion-like domains (PrLDs) have been identified in other
organisms, including humans, and they are generically named
prion-like proteins2.
The aggregated state of yeast prions is macroscopically indis-
tinguishable from that of pathogenic prions and amyloid proteins
involved in neurodegenerative diseases7. Thus, it has been assumed
that they all form amyloids through a common mechanism, which
involves misfolding of the native structure, either folded or dis-
ordered, into β-sheet aggregation-prone conformations8. However,
this generic and uncontrolled misfolding mechanism was difficult to
reconcile with the evidence that, in contrast to pathogenic amyloids,
the structural transitions of functional prions should be regulated.
Fiumara and co-workers demonstrated that yeast Q/N-rich PrDs
have an intrinsic propensity to form coiled-coils (CC), and they
proposed that CC-based structural changes might explain better the
physiological conformational switches of functional Q/N-rich
prions than stochastic misfolding9.
As yeast PrDs, polyQ tracts can adopt CC structures10; how-
ever, in this case, CC-mediated conformational changes might be
pathogenic. Several rare hereditary neurodegenerative diseases are
originated when Q stretches exceed a critical length, and their
severity increases with polyQ expansion11,12. These extensions
would result in longer CC-prone helices, with a stronger poly-
merization propensity, which might ultimately cause their
aggregation and the formation of the recurrent protein deposits
observed in these diseases9.
Although CC-mediated aggregation provides a plausible
mechanism for functional transitions in yeast PrDs and for the
pathogenesis of polyQ-expansion disorders, it remains to be
demonstrated that the aggregation of human prion-like proteins
also accommodates to the CC model. Therefore, we undertook a
bioinformatic analysis of the human proteome, which revealed
that a significant proportion of human PrLDs indeed contained
sequences of high CC propensity, which, in most cases, over-
lapped with Q-rich regions. This subgroup of prion-like proteins
works in the regulation of transcription, and it comprises key
transcription coactivators, including Mediator complex (Med-
iator) subunits 12 and 15 (MED12 and MED15).
Mediator is a large multi-protein complex that regulates most,
if not all, enhancer-driven gene transcription13–15. Mediator is
highly conserved among eukaryotes and consists of four modules:
head, middle, tail, and the CDK8 kinase module16. The head and
middle modules execute recruitment to the promoter regions,
while the tail module mediates protein interactions with the
transcription regulators at enhancers, and the CDK8 module is
involved in RNA Polymerase II (Pol II) recruitment and release15.
The tail module consists of 7 subunits, one of them being MED15,
which, as described above, we identified as a CC forming prion-
like protein.
MED15 is located in the cell nucleus, and its knockdown causes
slow growth and reduced transcriptional activation17. MED15 is
overexpressed in a wide range of human cancers: castration-
resistant prostate cancer, head, and neck squamous cell carcinoma,
hepatocellular carcinoma, breast cancer, renal cell carcinoma, and
testicular germ cell tumors18–25. Patients with MED15 over-
expression in tumor tissues exhibit a more aggressive phenotype,
associated with significantly shorter survival time18. Consequently,
MED15 may serve as a prognostic marker as well as a potential
therapeutic target in cancer.
The MED15 subunit was first discovered in yeast as Gal1126
and later on renamed as yMED1527. yMED15 is involved in a
variety of biological processes, such as the expression of galactose-
inducible genes, and it is an interaction hub of many transcription
factors (TFs)28. Interestingly, yMED15 contains a central Q-rich
region reported to form amyloid-like intracellular inclusions
spontaneously in yeast, whereas the aggregation of the full-length
yMED15 occurs under stress conditions29. The aggregation of
yMED15 provokes the loss of the entire tail module, reducing
transcription levels, which has been suggested to be an epigenetic
mechanism for transcription regulation, similar to those of clas-
sical yeast prions29.
Human MED15 (MED15) has a Q-rich region, consisting of
discontinuous polyQ tracts at its N-terminus, which maps to its
PrLD and is responsible for the predicted CC propensity of this
domain (Fig. 1A). yMED15 and MED15 have low sequence
identity and different distribution of their Q-rich regions; still,
this kind of low complexity sequences have been reported to exert
similar functions in orthologs without a strict positional
requirement10. Therefore, the MED15 prion-like domain
(MED15-PrLD) might possess cryptic amyloid and prion-like
features yet to be discovered.
Here, we provide experimental evidence that the MED15-PrLD
forms a dimer with CC structure. This domain bears the ability to
self-assemble into Congo Red (CR) positive, β-sheet enriched
amyloid fibrils, displaying concentration-dependent aggregation
kinetics, and self-seeding activity. Moreover, as in functional yeast
prions, a GFP globular domain adjacent to the PrLD maintains its
fold and activity in the amyloid state. We demonstrate that it is the
CC structure that regulates MED15-PrLD amyloid formation, its
chemical or genetic disruption abolishing aggregation. Expression
of MED15-PrLD in human cells promotes the formation of cyto-
plasmic and perinuclear inclusions, kidnaping the endogenous full-
length protein to these aggregates in a prion-like manner.
Overall, this study reveals that amyloid formation by human
prion-like proteins can follow the CC-mediated model reported
in yeast and that the amyloid and prion-like properties of MED15
are conserved across species, which suggests novel mechanisms
for MED15 function and malfunction.
Results
Human PrLDs with predicted coiled-coil domains overlap with
polyQ tracts. Coiled-coils (CC) are formed between proteins that
contain repeats of seven amino acids (a-b-c-d-e-f-g) in which
hydrophobic residues often occupy positions a/d to form a
hydrophobic layer between the coiling helices; these heptad
repeats are often discontinuous30,31. CC regions are over-
represented in yeast prions, overlapping with their Q/N-rich
prion domains, suggesting that the CC structure might represent
a defining feature of these domains in yeast9. This observation
prompted us to assess whether human prion-like proteins might
share the same architecture.
First, we performed a prion-like amino acid composition
(PLAAC) analysis to identify human prion-like proteins and their
respective PrLDs at the proteome level. PLAAC is an algorithm
that allows the identification of polypeptide regions with a
composition similar to that of a set of well-characterized yeast
PrDs32. We obtained a list of 193 reviewed human genes
encoding for proteins with PrLDs (Supplementary Data 1).
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We analyzed which of the identified PrLDs might fold into a CC
using COILS33, an algorithm that detects CC heptad repeats in
primary sequences (Supplementary Data 1). We found that 12% of
human PrLDs (n= 22) were predicted to have CC regions. In all,
86% of these proteins (n= 19) is involved in transcriptional
regulation (Supplementary Data 1). Accordingly, a Gene Ontology
(GO) analysis of the 22 candidates34 indicated a significant
enrichment in the following ontologies: (i) transcription initiation
from RNA polymerase II promoter in biological process, (ii)
transcription coactivator activity in molecular function, and (iii)
nucleus and nucleoplasm in cellular component (Supplementary
Data 1). Importantly, 90% of the predicted CC regions (n= 20)
correspond to or overlap with polyQ tracts in the PrLDs
(Supplementary Data 1 and Fig. S1), which is consistent with the
observation that polyQ proteins are functionally biased towards
transcriptional regulation10,35. These 20 prion-like candidates
include proteins whose polyQ expansion is connected to autosomal
dominant cerebellar ataxia, such as the TATA-box-binding protein
(TBP) and ATXN111, as well as the CREB-binding protein (CBP),
a transcriptional coactivator necessary for the survival of many
neurons which is recruited into aggregates in polyQ diseases36.
Overall, our analysis indicates that, as it occurs in yeast prions, a
significant fraction of human prion-like proteins might contain CC
that overlap with polyQ tracts at their PrLDs. Proteins displaying
these features include important transcriptional coactivators like
CBP, TBP, KMT2D, FOXP2, NCOA2, NCOA3, MAML2, MED12,
and MED15.
Apart from those involved in disease, the amyloid and prion-
like properties of the PrLDs identified in these transcriptional
regulators remain to be experimentally demonstrated. However,
the yMED15 polyQ can form amyloid-like aggregates on its
own29. Although human and yeast MED15 proteins display very
low sequence identity (12%), we decided that it was worthwhile to
explore whether the identified human MED15-PrLD can access
an amyloid state and propagate this conformation in a prion-like
manner.
MED15 contains an N-terminal Q-rich coiled-coil PrLD.
MED15 is highly enriched in Gln residues (Q, 20% of residues),
especially at its N-terminus, with multiple short polyQ tracts
(of 2–16 Qs; Fig. 1). It is precisely this N-terminal Q-rich region
that is identified as a PrLD by PLAAC (Fig. 1A and Supple-
mentary Data 1).
PrLDs are thought to be intrinsically disordered in their
monomeric states, in such a way that their self-assembly can
occur spontaneously, without an energy-dependent conforma-
tional change2. The MED15-PrLD is consistently predicted to be
disordered by FoldIndex and ESpritz predictors (Fig. 1A)37,38.
Disordered regions can be cryptic protein binding sites that, upon
interaction, undergo a disorder to order transition; DisoRDPbind
is an algorithm aimed to predict such transitions, scoring putative
associations between the disordered region of interest and RNA,
DNA, or protein39. MED15-PrLD was predicted to interact with
both RNA and protein (Fig. 1A), suggesting that it is susceptible
to experiment conformational switches. Indeed, polyQ tracts are
known to mediate protein–protein interactions (PPI) and multi-
merization, which can lead to the formation of homomeric or
heteromeric CC structures10. Accordingly, the MED15 N-
terminal Q-rich region is predicted to adopt a CC conformation
(Fig. 1A and Supplementary Data 1) and has been shown to
exhibit α-helical structure when fused to a globular domain40.
This CC domain is discontinuous and consists of three
consecutive CC regions (Fig. S2). As expected, in the MED15-
PrLD CC model, almost all “a” and “d” positions in the helix are
occupied by hydrophobic amino acids or Gln, which acts as an
ambivalent hydrophobe (Fig. 1B)41. The N-terminal Q-rich
segment is the less conserved region in MED15 vertebrate
orthologs, with significant differences in the number, length, and
Fig. 1 MED15 contains an N-terminal Q-rich coiled-coil PrLD. A MED15 diagram showing the location of the KIX (blue) and Q-rich (green) regions.
Prediction of prion-like domains using PLAAC32 and PAPA72 predictors, disorder regions using ESpritz38 and FoldIndex37 predictors, protein binding
regions using DisoRBPbind39 predictor, and coiled-coil regions using COILS33 and PairCoil270 predictors are shown below the diagram. B Schematic
diagram of the heptad repeats (a-b-c-d-e-f-g) predicted by COILS33 (14-residue window) of MED15-PrLD (residues 141–316). Gray residues indicate COILS
score <0.2.
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location of polyQ tracts among species; however, in all cases, it is
predicted to form CC (Fig. S2), suggesting that this region
is structurally conserved, likely, because of its functional
significance.
Overall, the bioinformatics analysis of MED15 suggests that we
are in front of a prion-like protein with a disordered N-terminal
Q-rich PrLD in its monomeric state, but with the ability to
undergo a transition to a dimeric or higher-order CC structure.
MED15 interactors are predicted to have coiled-coil domains.
Recently, a list of Mediator complex interactors was identified by
performing FLAG-MED15 immunoprecipitation in mice42.
Therefore, at least a fraction of the identified binders may contact
MED15 directly. All mouse MED15 potential interactors display
>75% sequence identity with their human homologs (Supple-
mentary Data 2). In the light of the predicted propensity of
MED15 to form CC, we examined the CC propensity of their
putative interactors using COILS33. Interestingly enough, 50% of
these candidates resulted in positive predictions, indicating that
CC-containing proteins are overrepresented among MED15
binders (Supplementary Data 2). Not surprisingly, a GO term
enrichment analysis indicated that this subset of proteins is
preferentially located at the nucleoplasm, acting as transcription
coactivators and with major involvement in Pol II transcription
(Supplementary Data 2). Importantly, among these polypeptides,
we found four of the CC-containing prion-like proteins identified
in the previous section: NCOA2, MAML2, CBP, and MED12,
which suggests that their PrLDs compositional bias and pro-
pensity to populate CC conformations might result in their
eventual interaction with MED15. Indeed, an analysis with the
STRING protein interactions database43, indicates that all these
five proteins are closely associated (Fig. S3; PPI enrichment
p-value: 7.5 × 10−08).
Soluble MED15-PrLD characterization. Long polyQ stretches
are commonly followed by polyproline (polyP) tracts at their C-
terminus. These repeats stabilize and stop the CC region10,44,
which suggests that the two tracts form a functional/structural
unit and that the expression of the polyQ alone may not reca-
pitulate the physiological context of the sequence. In MED15, a
Pro-rich segment is also adjacent to the Q-rich region (Fig. 1B),
and both stretches are predicted to be part of the PrLD. The
presence of Pro residues at the C-terminus of polyQ tracts is also
frequent in MED15 orthologs (Fig. S4).
Most proteins with polyQ tracts are modular, and these
stretches are in close vicinity to globular domains. Indeed, these
low complexity regions are difficult to express recombinantly and
to purify in the absence of a globular partner that modulates their
inherent aggregation propensity45. The MED15-PrLD is flanked
at its N-terminus by a globular KIX domain (Fig. 1A), a feature
conserved in MED15 orthologs (Fig. S4).
With the above considerations in mind, we expressed the
MED15-PrLD domain, containing both Q-rich and Pro-rich
regions, fused at the C-terminus of GFP, which would act as a
functionally traceable globular domain, hereinafter named as
GFP-MED15CC. This construct should allow us to characterize
the soluble, and eventually, the aggregated states of MED15-PrLD
in a mimic of its sequential framework.
As intended, GFP-MED15CC was purified from the soluble
cellular fraction. The GFP globular domain integrity was
evaluated by monitoring the GFP absorption and fluorescence
emission spectra (Fig. 2A, B). GFP-MED15CC spectral properties
were identical to those of GFP alone, with an absorption
maximum at 490 nm and an emission fluorescence maximum
at 510 nm. In order to verify that GFP-MED15CC was not
aggregated in the soluble state, we used synchronous light
scattering (Fig. 2C). Neither GFP nor GFP-MED15CC showed a
significant increase in light scattering signal, compared to the
buffer alone.
The GFP-MED15CC secondary structure was assessed by
far-UV circular dichroism (CD; Fig. 2D). GFP alone showed a β-
sheet spectrum with a characteristic minimum at 218 nm. In
contrast, the GFP-MED15CC spectrum exhibited two minima at
208 and 222 nm, characteristic of α-helices. The deconvolution of
the spectra using the K2D program46 indicated a predominant
α-helix conformation for GFP-MED15CC (100%) and β-sheet
for GFP (78%). Thus, the strong α-helix signal in GFP-MED15CC
completely masks the signal of GFP, something that is
characteristic of globular domains-CC fusions47.
As described above, MED15-PrLD is predicted to be
intrinsically disordered in its monomeric state. The fact that we
observed a predominant α-helical secondary structure by far-UV
CD is consistent with this region adopting a CC. This necessarily
implies that, in solution, GFP-MED15CC acquires quaternary
structure. GFP-MED15CC is 458 residues long, with an expected
MW of 52 kDa. Size exclusion chromatography (SEC) and native
PAGE were performed to evaluate the oligomerization state of
GFP-MED15CC (Fig. 2E, F). Its SEC elution pattern corre-
sponded to a protein size of ∼100 kDa (elution at 12.65 ml),
indicating that the protein was a dimer (Fig. 2E). In contrast, GFP
(246 residues, MW 28 kDa) was eluted as a monomer (elution at
15 ml). In agreement with the SEC data, GFP-MED15CC
migrates as a unique band of ∼100 kDa in a native PAGE,
located between the monomeric and dimeric forms of bovine
serum albumin (BSA) used as control (Fig. 2F). Besides, dynamic
light scattering (DLS) analysis revealed major populations with
average diameters of 13 and 7 nm for GFP-MED15CC and GFP,
respectively, further supporting that the MED15 CC domain
drives the formation of a dimeric structure.
In conclusion, in solution, GFP-MED15CC is a dimer
sustained by a CC interaction, where the adjacent globular
domain retains its integrity and function.
MED15-PrLD aggregates into β-sheet enriched amyloid-like
fibrillar structures. Both PrLDs and polyQ tracts are well known
for their ability to aggregate into amyloid β-sheet
conformations45,48. Therefore, we assessed if GFP-MED15CC
aggregates spontaneously using synchronous light scattering, GFP
fluorescence, far-UV CD, and infrared spectroscopy (ATR-FTIR;
Fig. 3A–D). GFP was used as a control in all these assays.
The proteins were incubated at 5 µM (0.25 mg/ml) for 24 h at
37 °C under quiescent conditions, and the light scattering of the
correspondent solutions measured (Fig. 3A, B). In contrast to
GFP, GFP-MED15CC exhibited a substantial increase in the light
scattering signal upon incubation (Fig. 3A). GFP fluorescence was
examined in the samples’ supernatant after their centrifugation
(see Methods section). In agreement with the light scattering data,
the fluorescence of the GFP-MED15CC in the soluble fraction
decreased significantly upon incubation, whereas that of GFP
remained mostly the same (Fig. 3B). Together, these results
demonstrate that GFP-MED15CC aggregates within 24 h.
We monitored the secondary structure of incubated GFP-
MED15CC solutions by far-UV CD and fourier transform
infrared (FTIR; Fig. 3C, D). GFP-MED15CC suffered a
conformational change from the initial α-helical to a β-sheet
structure after 24 h of incubation, displaying a spectrum
minimum at 218 nm, similar to that of GFP (Fig. 3C). Prolonged
incubation for 4 days resulted in a weak β-sheet signal, indicating
that a significant proportion of the protein was aggregated out of
the solution, becoming undetectable by CD. The conformation of
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-01930-8
4 COMMUNICATIONS BIOLOGY |           (2021) 4:414 | https://doi.org/10.1038/s42003-021-01930-8 | www.nature.com/commsbio
control GFP remained unaffected after 4 days of incubation
(Fig. S5). To further confirm the putative β-sheet secondary
structure of incubated GFP-MED15CC, we analyzed its FTIR
spectrum in the amide I region (1700–1600 cm−1), which
corresponds to the absorption of the main chain carbonyl group
and is sensitive to the protein conformation. Deconvolution of
the FTIR spectrum of incubated GFP-MED15CC resulted in a
major peak at 1625 cm−1, which is typically attributed to the
presence of intermolecular β-sheet structure (Fig. 3D), in good
agreement with the CD data.
Next, we evaluated whether GFP-MED15CC aggregates were
arranged into an amyloid-like architecture. GFP-MED15CC
emits green fluorescence; hence, we could not use Thioflavin-
T49. Instead, we used a CR precipitation assay since this dye
Fig. 2 MED15-PrLD soluble characterization. A Absorbance, B fluorescence, C light scattering, and D circular dichroism of 5 μM GFP and GFP-MED15CC.
E GFP-MED15CC size exclusion chromatography elution profile. Filled circle and empty circle in the x axis indicates 100 and 50 kDa position, respectively.
F 12.5% blue native PAGE of GFP-MED15CC and bovine serum albumin (BSA) at 0.5 mg/ml. All assays are performed in 20mM Tris pH 7.5 and
150mM NaCl.
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deposits on top of amyloid fibrils50. We incubated CR with buffer
only, or with GFP, as negative controls, and with Sup35NM yeast
prion amyloid fibrils as a positive control5. After 1 h of
incubation, only GFP-MED15CC and Sup35NM formed a red
pellet, suggesting that MED15CC aggregates are amyloid-like
(Fig. 3E). Next, we addressed the morphological features of GFP-
MED15CC aggregates by transmission electron microscopy
(TEM) to further confirm its amyloidogenic nature (Fig. 3F).
Negative staining showed long, thin, and unbranched amyloid-
like fibrillar structures, without any significant accumulation of
amorphous material. The fibrils exhibited a diameter of 19 ± 4 nm
and a length of 2 ± 0.5 µm.
In contrast to pathogenic proteins, a remarkable property of
yeast PrDs is that their assembly into amyloids does not
necessarily imply the misfolding of the attached globular
domains, which might keep their native conformation in the
aggregated state51. In the same manner, GFP-MED15CC fibrils
were green fluorescent, indicating the maintenance of the native
GFP fold within the fibril phase (Fig. S6).
Overall, these results indicate that the PrLD of the initially
dimeric GFP-MED15CC protein promotes the spontaneous
assembly into supramolecular β-sheet enriched fibrillar amyloid
structures in which the adjacent globular domain keeps its
functional conformation, all these features being consistent with a
prion-like nature.
MED15-PrLD aggregation kinetics. In the previous section, we
showed that GFP-MED15CC aggregates into amyloid fibrils. To
further characterize this reaction, we followed its kinetics, at 5 µM
protein concentration and 37 °C without agitation. We monitored
the reaction by synchronous light scattering, far-UV CD, and GFP
fluorescence (Fig. 4A–D). Upon incubation, GFP-MED15CC
showed a progressive increase in light scattering, indicative of
protein aggregation (Fig. 4A). Far-UV CD analysis indicated that
Fig. 3 MED15-PrLD aggregates into β-sheet enriched amyloid-like fibrillar structures. A Light scattering, B GFP fluorescence (supernatant fraction) and
C circular dichroism of soluble (t=0 h, black) and aggregated (t= 24 h, red, or t= 4 days, blue) 5 μM GFP-MED15CC or GFP. D FTIR of aggregated (t= 24 h)
5 μM GFP-MED15CC. E Congo Red precipitation of incubated (t= 9 h) 5 μM GFP, GFP-MED15CC, GFP-MED15PP, and 10 μM Sup35NM. F Transmission
electron microscopy image of aggregated (t= 9 h) 5 μM GFP-MED15CC. All assays are performed in 20mM Tris pH 7.5 and 150mM NaCl.
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this is accompanied by a conformational change from an α-helical
to a β-sheet secondary structure (Fig. 4B). GFP-MED15CC sample
centrifugation at the same time points confirms a gradual decrease
in the amount of soluble protein, with a concomitant decrease of
GFP fluorescence in the supernatant (Fig. 4C, D). All the techniques
converge to indicate that 9 hours of incubation are enough to reach
the plateau phase of the aggregation reaction. In contrast, the
parallel GFP control did not show signs of aggregation by any of the
used techniques (Figs. 3A–C and 4D).
Aggregation into amyloids responds to a second or higher
reaction and thus is, typically, very sensitive to the protein
concentration. We evaluated if this is the case for GFP-MED15CC.
We monitored GFP-MED15CC aggregation kinetics at 5 and
25 μM by synchronous light scattering and observed a clear
acceleration and signal increase at the higher concentration, as
expected for a canonical amyloid protein (Fig. 4E).
Many amyloids, and specially prion-like proteins, have the
ability to self-propagate by seeding the aggregation of their
soluble counterparts52. In this way, the presence of small
amounts of preformed amyloid fibrils usually accelerates the
protein aggregation kinetics, mostly by reducing or even
abrogating the lag phase of the reaction, which corresponds to
Fig. 4 MED15-PrLD aggregation kinetics characterization. A Light scattering, B circular dichroism, and C GFP fluorescence (supernatant fraction) of 5 μM
GFP-MED15CC incubated at 37 °C at the indicated time points. D 12% SDS-PAGE of 5 μM GFP and GFP-MED15CC supernatant fraction after
centrifugation at the indicated time points of incubation. E Light scattering kinetics of 5 and 25 μM GFP-MED15CC at 37 °C. The inlet shows the real
scattering intensities at the final time point (9 h, gray rectangle). F Light scattering kinetics of 5 μM GFP-MED15CC incubated at 37 °C in the absence or
presence of 2% GFP-MED15CC seeds. Kinetics of seeds alone is shown as control. All assays are performed in 20mM Tris pH 7.5 and 150mM NaCl.
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the formation of the initial aggregation nuclei. In Fig. 4F we
compare the aggregation kinetics of GFP-MED15CC at 5 µM in
the absence or presence of 2% (w/w) of its preformed fibrils. It
can be observed how the presence of fibrils dramatically
accelerates GFP-MED15CC aggregation. This result indicates
that GFP-MED15CC amyloid formation follows a nucleation-
polymerization mechanism and that, at least in vitro, the
MED15-PrLD can propagate its amyloid conformation.
MED15-PrLD aggregation is governed by its coiled-coil con-
formation. Pathogenic polyQ tracts are generally thought to
misfold spontaneously into aggregation-prone β-sheet con-
formations. However, recent evidence suggests that their aggre-
gation depends instead on the population of metastable CC
structures9. To test whether this mechanism drives GFP-
MED15CC amyloid formation, we evaluated its aggregation in
the presence of two reagents aimed at weakening or strengthening
the CC domain selectively.
In the presence of 2 M urea, the GFP-MED15CC α-helical
conformation was significantly disrupted, as assessed by far-UV
CD, and the spectrum shifted towards the disordered region
(Fig. 5A). Importantly, the control GFP conformation was not
affected by this denaturant (Fig. S7A). We analyzed the GFP-
MED15CC aggregation propensity in the presence or absence of
2 M urea by synchronous light scattering and GFP fluorescence
(Fig. 5B, C). GFP-MED15CC did not show any signs of
aggregation in the denaturing agent’s presence, indicating that
CC disruption prevented protein aggregation. It is important to
point out that, as expected, the integrity of the GFP moiety of
GFP-MED15CC was not affected by urea because the protein
remained fluorescent. The control GFP did not show any
aggregation with, or without, urea (Fig. S7B, C).
TFE is a reagent used to enhance or stabilize α-helical
conformations. However, the presence of >20% TFE might induce
non-native α-helices, blurring any physiologically relevant inter-
pretation of the data; to avoid this effect, we used an unusually low
concentration of this cosolvent in our experiments. In the presence
of 5% TFE, the CC of GFP-MED15CC was significantly enhanced
as observed by far-UV CD (Fig. 5D), whereas the structure of the
control GFP was unaffected (Fig. S7D). Evaluation of GFP-
MED15CC aggregation kinetics by synchronous light scattering
and GFP fluorescence showed a significant acceleration of the
process in the presence of TFE (Fig. 5E, F). Control GFP did not
show signs of aggregation with, or without, TFE (Fig. S7E, F).
MED15-PrLD contains discontinuous CC segments, account-
ing for a total of 11 heptad repeats, according to the COILS
predictor (Fig. 1B). To confirm the predominant role of MED15
CC on the PrLD aggregation, we used structure-guided
Fig. 5 MED15-PrLD aggregation is governed by its coiled-coil conformation. A Circular dichroism, B light scattering, and C GFP fluorescence
(supernatant fraction) of 5 μM GFP-MED15CC in the absence or presence of 2M urea. D Circular dichroism, E light scattering kinetics, and F GFP
fluorescence kinetics (supernatant fraction) of 5 μM GFP-MED15CC in the absence or presence of 5% TFE. G Circular dichroism, H light scattering, and
I GFP fluorescence kinetics (supernatant fraction) of 5 μM GFP-MED15CC or GFP-MED15PP. In all cases, aggregation was performed for 9 hours at 37 °C
without agitation in 20mM Tris pH 7.5 and 150mM NaCl.
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mutagenesis to decrease the CC propensity by introducing Pro
substitutions in the wild-type protein, a strategy commonly used
for α-helix disruption53. We substituted five residues in positions
“a” of the heptad repeats with a single Pro (Fig. S8A). These
substitutions are predicted by COILS to disrupt the CC domain
significantly (Fig. S8B). Hereinafter we named this mutant as
GFP-MED15PP.
We first analyzed GFP-MED15PP secondary structure in
solution by far-UV CD. The variant exhibited a minimum at
205 nm correspondent to a random coil conformation, although a
small shoulder at 222 nm was still evident. In any case, the
spectrum confirmed that the CC fold was significantly destabi-
lized/disrupted by the introduced amino acid changes (Fig. 5G).
Consistent with this observation, the GFP-MED15PP aggregation
propensity was clearly reduced, relative to the GFP-MED15CC
protein, as evidenced by the synchronous light scattering and GFP
fluorescence signals after 9 h of incubation at 37 °C (Fig. 5H, I).
Indeed, when incubated under the same conditions that GFP-
MED15CC, the mutant protein does not bind to CR (Fig. 3E).
All in all, these results indicate that its CC conformation
mediates MED15-PrLD amyloid formation and that disruption of
this structure significantly reduces its aggregation potential. This
aggregation mechanism is consistent with the one described for
the functional switch of Q/N-rich yeast prions9.
MED15-PrLD forms insoluble cytoplasmic inclusions in
mammalian cells and kidnaps the endogenous protein. In the
previous sections, we have shown that MED15-PrLD forms
amyloids and that the CC is a central player in this reaction. To
determine whether MED15-PrLD may aggregate in a cellular
context, we stably transfected HEK293T cells with lentiviral vec-
tors containing EGFP-tagged MED15-PrLD (EGFP-MED15CC)
or EGFP, as a control, and expressed the two proteins using a
doxycycline-inducible system (TetO).
MED15 is a component of the Mediator tail module, and, as
expected, it displays a diffuse nuclear localization in non-induced
cells (Fig. 6A). In all, 24 h after induction of protein expression
EGFP-MED15CC formed small aggregates distributed homo-
genously in the cytoplasm, whereas at 72 hours multiple larger
cytoplasmic and perinuclear inclusions where observed, whereas
EGFP remained diffusely distributed in the cell (Fig. 6A).
As in the case of HEK293T cells, transfection of HeLa cells with
lentiviral vectors containing EGFP-MED15CC or EGFP and
expression of the two proteins using the TetO-system resulted in
the aggregation of EGFP-MED15CC in the cytoplasm, with EGFP
remaining soluble (Fig. S9A).
To demonstrate that the EGFP-MED15CC ability to form
intracellular inclusions is expression system independent and that
this feature depends on the CC region of the PrLD, we transiently
transfected EGFP, EGFP-MED15CC, and the EGFP-MED15PP
variant, containing the five disrupting Pro substitutions, in HeLa
cells and expressed the three proteins for 24 hours. EGFP-
MED15CC expression resulted again in the formation of
cytoplasmic and perinuclear inclusions, which occur in ∼50%
of the transfected cells (Figs. 6B, C and S9B). In contrast, EGFP-
MED15PP formed inclusions in only ∼15% of the transfected
cells (p-value= 0.0063), and they were small (Fig. 6B, C).
Inclusion formation is a hallmark of protein aggregation, and
aggregated amyloids exhibit protein detergent insolubility. In
agreement with their relative in vitro amyloid-forming and
Fig. 6 MED15-PrLD forms insoluble cytoplasmic inclusions in mammalian
cells. A Cellular localization by immunofluorescence of EGFP or EGFP-
MED15CC in HEK293T cells after addition of doxycycline (doxy) for 0, 24,
or 72 h. B Cellular localization by immunofluorescence of EGFP, EGFP-
MED15CC, and EGFP-MED15PP in HeLa cells after expression for 24 h. In
both A and B, cells were stained with MED15 antibody (red) to evaluate the
effect of transfection in the endogenous mediator subunit, and with DAPI
(blue) as nuclear marker. C Graph of percentage transfected cells
containing cytoplasmic of perinuclear aggregates after EGFP, EGFP-
MED15CC, and EGFP-MED15PP expression in HeLa cells. Dots represent
the mean of independent triplicates.
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cellular inclusion-forming propensities, EGFP-MED15CC was
localized mainly in the detergent-insoluble fraction upon HeLa
cells fractionation, whereas EGFP-MED15PP remained mostly
soluble (Fig. 7A).
Overall, the cellular data converge to indicate that, as it happens
in vitro, the CC conformation mediates MED15-PrLD aggregation
and the formation of protein inclusions in human cells.
We have shown that, in vitro, the MED15-PrLD seeds the
amyloid formation of its soluble counterpart efficiently. This
activity immediately suggested that, when expressed in cells, it
may transmit its amyloid-like state and potentially seed the
aggregation of the endogenous, soluble, and functional MED15
protein. Western blot and immunostaining of the endogenous
full-length MED15 indicate that EGFP-MED15CC transient
expression in HeLa cells results in a fraction of the otherwise
soluble endogenous MED15 being recruited into the detergent-
insoluble fraction (Fig. 7B). This pro-aggregation effect was
reduced when we expressed the CC-disrupted EGFP-MED15PP
variant instead (Fig. 7B).
Despite MED15 is assumed to be a nuclear protein, its presence
in the cytosol has been described24 and it has been suggested that
this subunit might experiment indirect nuclear export/import
through a piggyback mechanism54. We speculated that seques-
tration of the endogenous protein by aggregated MED15-PrLD
should increase its levels in the cytosol. HeLa cells fractionation
into cytoplasmic and nuclear fractions confirmed the expected
redistribution of the endogenous protein upon EGFP-MED15CC
expression (Fig. 7C). Mislocalization of endogenous MED15 in
the cytosol might result from the retention of newly synthesized
protein and/or by an alteration of the nucleo-cytoplasmic
shuttling. In both cases, the interaction with aggregated cytosolic
EGFP-MED15CC will difficult the transit to the nucleus.
Next, we assessed if the mislocalization of endogenous MED15
might also alter the distribution of other subunits of the Mediator
complex, particularly MED14, MED12, and MED1, placed at the
tail, CDK8, and middle modules, respectively. In contrast to
MED15, none of these endogenous subunits mislocalizes upon
expression of EGFP-MED15CC (Fig. 7C), which indicates that as
expected for a prion-like protein mechanism, cytoplasmic
recruitment is sequence-specific.
Overall, the data in this section converge to indicate that
MED15-PrLD possesses intracellular prion-like activity, related to
the CC propensity of its Q-rich segment.
Discussion
We have identified the presence of CC domains in a significant
number of human PrLDs. This result extends the previous
observation that these α-helical domains were recurrent in yeast
prions9, indicating that CC constitute a generic feature of many
functional prion and prion-like proteins.
PrLDs are considered and consistently predicted to be dis-
ordered in their soluble states. Accordingly, a disordered to β-
sheet transition is seen as the generic mechanism behind their
aggregation, similar to pathogenic amyloids3,4. Instead, our data
are consistent with CC domains playing a critical role in the
structural dynamics of at least a fraction of human PrLDs.
Accordingly, disrupting or destabilizing the MED15-PrLD CC,
either genetically, by Pro mutations, or chemically, with urea,
abolishes amyloid formation, whereas its stabilization with TFE
accelerates aggregation.
To the best of our knowledge, this is the first time that the
transition of a complete PrLD from an initial soluble CC con-
formation to an amyloid state has been characterized biophysi-
cally since previous reports involved relatively short peptides (17
residues) of the yeast Ure2p PrD9. These studies did not allow to
discriminate if α-helical CC were self-sufficient mediators of the
aggregation of functional prions or just intermediates or facil-
itators in the process of β-sheet formation. Our results support
this second mechanism because the spontaneous aggregation of
MED15-PrLD into amyloid fibrils involves a progressive con-
formational shift from an initial α-helical state to a β-sheet-rich
structure, which occurs concomitantly with the aggregation of the
domain.
Fig. 7 MED15-PrLD solubility and endogenous MED15 localization in HeLa cells. Cell extracts of HeLa were processed for soluble examination of A EGFP,
EGFP-MED15CC (CC), and EGFP-MED15PP (PP) or B endogenous MED15 by western blot in untransfected (untransf) cells or after expression of EGFP,
EGFP-MED15CC (CC), or EGFP-MED15PP (PP) proteins. EEA1 and GAPDH were blotted as loading controls. C Cell extracts of HeLa were processed for
nuclear/cytoplasmic (N/C) examination of endogenous MED15, MED14, MED12, and MED1 mediator subunits by western blot after expression of EGFP or
EGFP-MED15CC (CC) proteins. LaminA/C, H3K9me3, and GAPDH were blotted as loading controls.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-01930-8
10 COMMUNICATIONS BIOLOGY |           (2021) 4:414 | https://doi.org/10.1038/s42003-021-01930-8 | www.nature.com/commsbio
The molecular mechanism by which a given CC converts into a
β-sheet and forms amyloids is still unclear. In an elegant study,
Kammerer et al.55 designed a short peptide (17 residues), referred
to as ccβ, that folds into a CC under ambient conditions but
transforms into amyloid fibrils at elevated temperatures. This
allowed the authors to trigger the CC to β-sheet transition in a
controlled manner and to dissect the relative importance of the
forces driving this conformational change. The study revealed
that the nature of residues at position “f” of the heptad repeat, the
most exposed region in a CC, was the most critical feature for
the peptide transition. Hydrophobic residues at this position
dramatically accelerated aggregation, whereas polar amino acids
abolished it. These hydrophobic residues would facilitate multi-
merization, a reaction that depends on local contacts and would
be favored at increased protein concentrations. Besides, a
hydrophobic amino acid at position “f” would allow forming a
continuous hydrophobic patch in a β-sheet, together with
hydrophobic residues in positions “a” and “d”, all lying in one
side of the sequence in a fully extended conformation56. The same
mechanism would likely apply for polyQ tracts, since Gln behaves
as an ambivalent hydrophobe41, with contacts becoming more
favorable as the polyQ, and therefore the CC, expands.
Although our model system is far more complex, it shares
significant features with the behavior of ccβ. In both cases, CD
data indicated a transition from an initial α-helical to a β-sheet
structure, the aggregated states corresponded to ordered amyloid
fibrils, and conformational conversions were significantly accel-
erated by increased protein concentrations. Importantly,
according to COILS, all residues at position “f” of the MED15-
PrLD CC domain are either hydrophobic or Gln (Fig. 1B). The
need for specific spatial positioning of exposed hydrophobic
residues to allow multimerization might explain the need to
maintain the integrity of CC for MED15-PrLD aggregation. An
essential difference between ccβ and MED15-PrLD is that the
structural transition of the former requires native state destabi-
lization by temperature, whereas in the second case, it occurs
spontaneously at room temperature. This indicates that the
energy barrier between the CC and amyloid states of MED15-
PrLD is significantly lower than that of ccβ, something expected
for a domain that should experiment conformational shifts under
physiological conditions.
A CC-mediated model does not exclude the interplay of CCs
with other PrLD elements in the aggregation process. The pre-
dicted CC regions in MED15-PrLD are discontinuous, with two
short regions devoid of significant α-helical propensity linking
them (Fig. 1B). We have shown that a majority of yeast PrDs
contain sequence stretches able to assemble into highly ordered
amyloid fibrils57. These regions differ from the classical amyloid
cores of pathogenic proteins in that they are slightly longer and
more polar, in such a way that the amyloid potential is less
concentrated, allowing the containing PrD to remain soluble
under most physiological conditions, while still keeping a certain
amyloid propensity that might facilitate assembly in certain
circumstances57,58. These soft amyloid cores (SAC) are necessary
to sustain yeast prions conversion in human cells59. We recently
identified and characterized similar regions within several human
PrLDs, including that of MED1560. The SAC of MED15-PrLD
comprises residues 184-QQQQQFQAQQSAMQQQFQAVV-204
and a peptide correspondent to this stretch spontaneously forms
highly ordered, β-sheet-rich, amyloid fibrils60. This SAC corre-
sponds almost precisely to the connecting region between the first
and second CC in MED15-PrLD (Figs. 1B and 8A). This sequence
is predicted to be devoid of any CC propensity by COILS and
completely disordered by both FoldIndex and Espritz, and
accordingly to be significantly exposed to the solvent. Thus,
contacts between these accessible regions in different MED15-
Fig. 8 MED15 soft amyloid core seeds MED15-PrLD aggregation. A Schematic diagram of MED15-PrLD structure. It consists of three coiled-coil regions
predicted by COILS33 (14-residue window) separated by disordered regions. The disorder region between the first and second coiled-coil corresponds to
the soft amyloid core (SAC) predicted by pWaltz73. The final disordered region corresponds to the Pro residues flanking the polyQ tracts (polyP
disordered). B Transmission electron microscopy image of aggregated 100 μM MED15CC SAC in 20mM Tris pH 7.5 and 150mM NaCl. C Light scattering
kinetics of 5 μM GFP-MED15CC incubated at 37 °C in the absence or presence of 2% MED15 SAC seeds (peptide seeds). Kinetics of seeds alone is shown
as control. Aggregation was performed in 20mM Tris pH 7.5 and 150mM NaCl.
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PrLD molecules are possible. Indeed, when we formed fibrils of
the 21-residues peptide (Fig. 8B) and added them (2%) to a
solution of soluble GFP-MED15CC, they efficiently seeded its
aggregation, indicating that this region was recognized in the
soluble and dimeric protein (Fig. 8C). However, it is important to
note that this amyloidogenic sequence alone is not sufficient to
promote aggregation since this reaction does not occur in the
absence of a previous CC conformation. Thus, either α-helical
regions drive the initial MED15-PrLD multimerization, and
intermolecular SAC contacts occur afterward, or both regions act
in parallel to mediate aggregation. In both instances, the presence
of the SAC would contribute to decrease the energy barrier for
amyloid formation, respect that of a CC-only driven reaction.
This leads us to propose a mechanism in which both the mis-
folding of short disordered regions to β-sheet conformations and
CC multimerization cooperate to promote MED15-PrLD amyloid
formation, unifying thus two apparently contradictory models
for prion conversion. Such a cooperative model would explain
why MED15-PrLD fibrillates spontaneously, even if its polyQ
tracts are much shorter than those in triplet expansion genetic
diseases61.
We show that a dimeric CC structure is the thermodynamically
dominant MED15-PrLD form in solution, immediately suggest-
ing that MED15 might form homodimers spontaneously. No
studies on the oligomeric state of full-length MED15 are available,
but it has been demonstrated that yMED15 assembles into a
dimer over a broad range of concentrations, suggesting that this
state is also accessible to MED1562. The existence of functional
MED15 as a dimeric protein stabilized by CC contacts is con-
sistent with the observation that proteins containing CC are
overrepresented among its interactors, since apart from homo-
typic interactions, CC also facilitate heterotypic PPI63. Human
prion-like proteins containing CC at their PrLDs function in
transcriptional regulation and comprise important coactivators,
including NCOA2, MAML2, CBP, and MED12, all inter-
connected with MED15. As in humans, transcription regulators
are prevailing in the yeast prion family6, and they include four
bona fide prions: Ure2p, Swi1, Cyc8, Mot3. Not surprisingly,
Fiumara et al.9 demonstrated that all these proteins contain CC at
their PrDs. Thus, transcription appears to be an important cel-
lular event that is influenced by prions and prion-like proteins
across species, likely thanks to their ubiquitous CC domains. As it
occurs in yeast, human prion-like transcription coactivators
might permit the generation of phenotypic heterogeneity, allow-
ing cells to adapt in front of intrinsic and extrinsic changes.
For most yeast prions, the new phenotype arising from their
conversion to the amyloid state arises from a loss of function. In
this way, Ure2p is a dimeric protein whose globular functional
domain binds to the transcription factor Gln3p, preventing its
migration to the nucleus64. This interaction is lost in the Ure2p
prion amyloid state, allowing Gln3p to activate the transcription
of a series of genes that were previously silent. However, the
Ure2p globular domain is not misfolded in the process and
maintains its original fold but becomes occluded from interaction
and loses its original function51. Similarly, when MED15-PrLD
accesses a highly ordered amyloid state, the contiguous GFP
moiety remains folded and fluorescent, suggesting that a
mechanism equivalent to that of Ure2p might regulate MED15
activity.
In vitro, preformed fibrils of MED15-PrLD can seed the
aggregation of their soluble counterpart, implying that they
facilitate a conformational conversion from an initial α-helical to
a β-sheet structure. When MED15-PrLD is expressed in human
cells, a significant fraction of the endogenous MED15 protein
localizes to the detergent-insoluble cytoplasmic fraction suggest-
ing that an analogous mechanism applies inside cells and thus
that MED15 can act in a prion-like manner in a physiological
context. The ability to aggregate inside cells and to potentially
transmit this conformation is, again, strongly dependent on the
integrity of the N-terminal CC domain, as demonstrated by the
reduced ability to form cellular inclusions and to interact with the
endogenous protein of the MED15PP variant.
MED15 is part of the mediator tail module and is known to
serve as a hub for signaling pathways. MED15 is overexpressed in
different cancers and correlates with the clinical outcome and the
recurrence of the disease18–20,23,65. The molecular mechanism by
which increased levels of MED15 contributes to these malign
phenotypes remains unknown, but it is assumed that they result
from an increased and sustained transcriptional activation19,20,23.
MED15-PrLD forms intracellular inclusions in different human
cell lines, including laryngeal and oral squamous cell carcinoma
(Fig. S10), two tumors with MED15 implication19. Under the
assumption that, as it occurs for yMED15, the aggregation pro-
pensity of the PrLD is maintained in the context of the full-length
protein, our results suggest alternative mechanisms to explain the
association of this prion-like protein with cancer. Overexpression
would increase the number of MED15 pre-associating N-terminal
CC domains and thus their effective local concentration, facil-
itating both the establishment of CC homotypic and heterotypic
interactions and PrLD conformational conversion.
MED15-PrLD mediated homotypic interactions would favor
multimerization, and this might prevent the establishment of
other relevant MED15 PPI, occluding the access to TFs inter-
acting motifs, like those in the KIX domain, as it happens in yeast
Ure2p51. Alternatively, the self-association of MED15 might
result in enhanced formation of transcriptional hubs by phase
separation, as described for the ENL chromatin reader66. Both
situations are expected to result in widespread transcriptional
changes. Because a significant fraction of MED15 interactors
contains CC domains, increased heterotypic interactions and
subsequent multimerization by side-to-side CC interactions, or
from the swapping between protomers, are expected to exert a
similar effect to homotypic contacts, either decreasing or
exacerbating the interactors function. Another possibility is that
the MED15-PrLD would establish promiscuous interactions with
other Q-rich CC-containing proteins that are not usual MED15
partners, sequestering them. Since many of these proteins are
expected to be TFs, these degenerated CC interactions would
significantly impact transcription and signaling pathways, as
demonstrated for polyQ-expanded proteins in neurodegenerative
diseases11,67. In extreme cases, the MED15-PrLD might template
and enhance the transition of other Q-rich proteins towards the
formation of toxic amyloid aggregates, as previously shown for
human ATXN140. Deciphering if any of these mechanisms or a
combination of them is behind MED15 association with different
cancers might offer novel therapeutic avenues for their treatment.
Methods
Bioinformatics analysis. Human reviewed proteins from the standard proteome
(Proteome ID UP000005640, release 2019_06) were downloaded from UniProtKB/
Swiss-Prot68,69. MED15 mouse interactors were obtained from42. Their human
homologous were obtained by blasting each sequence against their human Uni-
ProtKB/Swiss-Prot counterparts. For each protein, the highest sequential candidate
(>75% homology) was obtained.
Human reviewed proteins were screened with PLAAC algorithm32 using as
background probability the precompiled frequencies of human proteome to obtain
the list of putative proteins with PrLDs.
Coiled-coil prediction was performed using the C version of COILS33 or
PairCoil270 with window length of 21 residues, unless is otherwise indicated.
Prion-like proteins and MED15 interactors datasets were analyzed for
enrichment with the Functional Annotation Tool of DAVID 6.8 (Database for
Annotation, Visualization and Integrated Discovery)34 and ordered by p-value. The
default “Direct GO” category was selected for the three ontologies: molecular
function, biological process and cellular component. Direct GO uses mappings
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directly provided by the source annotation, thus minimizing redundant parent
terms or very high-level classes.
MED15 sequences. MED15-PrLD sequence (residues 141–316) was obtained from
Erich E. Wanker research group and fused to GFP sequence in pET21b plasmid.













MED15 PP sequence was purchased from Genscript as GFP-MED15PP fusion
in a pET21b plasmid. The sequence is the same as GFP-MED15CC except 5 Pro
substitutions in MED15 CC region (Fig. S6A).
Protein expression and purification. In all, 100 ml of Luria Broth (LB) with 100
μg/ml ampicillin (amp) and 34 μg/ml chloramphenicol (clm) were inoculated by
single colony of BL21 Rosetta cells with pET21b-GFP-MED15CC/PP and incu-
bated overnight at 37 °C and 250 rpm. In total, 25 ml of saturated overnight culture
was transferred into 1L LB-amp-clm and incubated at 37 °C and 250 rpm. Protein
expression was induced at OD600= 0.5 by addition of isopropyl-β-D-thiogalacto-
pyranoside (IPTG) to a final concentration of 0.5 mM. The induced culture was
incubated O/N at 20 °C and 250 rpm. Cells were then harvested by centrifugation
for 15 min at 4000×g and 4 °C (Beckman CoulterTM Avanti Centrifuge J-26XPI).
The cell pellet was frosted at −80 °C.
Pellets from 2L cell culture were resuspended in 30 ml binding buffer (20 mM
TrisHCl pH 8, 500 mM NaCl, 20 mM imidazole, 10% glycerol) supplemented with
0.2 mg/ml lysozyme, 20 µg/ml DNase, and 1 tablet of protease inhibitor cocktail
EDTA free (Roche). The suspension was incubated for 20 min at 4 °C with slow
agitation and then lysed by 5 min sonication on ice (Branson Digital Sonifier).
Lysate cells were centrifuged for 30 min at 30,000×g and 4 °C. The supernatant was
filtered through a 0.45-µm PVDF membrane and loaded onto a HisTrap FF Ni-
column (GE Healthcare) at a flow rate of 4 ml/min. Protein was eluted by one-step
procedure using elution buffer (20 mM TrisHCl pH 8, 500 mM NaCl, 250 mM
imidazole, and 10% glycerol). His purified protein was treated with 0.2 mg/ml
RNase (Thermo Scientific) for 15 min at 37 °C and 1mM PMSF was added to avoid
protein degradation. Native buffer (20 mM TrisHCl pH 8, 500 mM NaCl, and 10%
glycerol) was added to the protein sample to reduce imidazole to 20 mM and a
second His trap step was performed as before. Then, protein was filtered using 0.22
µm PVDF membrane, concentrated using 10 K Amicon (Millipore) to 2.5 ml,
filtered again and subjected to PD10 column equilibrated in 20 mM TrisHCl pH
7.5, 500 mM NaCl, 10% glycerol. Purified protein was concentrated to 400 μM,
filtered and stored in small volume aliquots at −80 °C. Protein concentration and
absence of RNA was confirmed by 260 nm and 280 nm absorbance values using
Specord® 200 Plus spectrophotometer (Analyticjena).
GFP was purified as described in Gil-Garcia et al.71 and Sup35NM was purified
as described in Sant’anna et al.57.
Size exclusion chromatography. In all, 2 mg/ml of purified protein was filtered
with 0.22 µm PVDF membrane and loaded on a Superdex 200 HR 10/30 (GE
Healthcare) equilibrated with 20 mM TrisHCl pH 7.4, 150 mM NaCl, and 10%
glycerol. The fractions were analyzed by 12% SDS-PAGE.
Native page. In all, 0.5 mg/ml of purified protein was loaded in a 12.5% blue native
polyacrylamide gel electrophoresis for the analysis of protein oligomers.
Dynamic light scattering. GFP and GFP-MED15CC protein size was determined
using a Malvern Zetasizer Nano Series (Malvern instruments, UK) in 20 mM
TrisHCl pH 7.5 and 150 mM NaCl at different protein concentrations per dupli-
cate. Protein diameter was extracted from volume size.
GFP absorption. GFP absorbance was monitored from 400 to 600 nm using a
Specord® 200 Plus spectrophotometer (Analyticjena).
Protein aggregation. Right before each experiment, the stock solutions were
diluted to 5 μM in 20mM TrisHCl pH 7.4 and 150 mM NaCl. For aggregation
assays the samples were incubated at 37 °C without agitation. In some experiments,
protein aggregation was performed in the presence of 2M urea or 5% 2,2,2-
trifluoroethanol (TFE) (Fluka). All aggregation experiments were performed per
triplicate.
GFP fluorescence. In all, 50 μl sample was centrifuged for 5 min at max speed and
RT. Then, supernatant fraction was used for GFP fluorescence measurements
unless indicated in the text. GFP fluorescence was monitored using a JASCO
Spectrofluorometer FP-8200. The conditions of the spectra acquisition were:
excitation wavelength of 485 nm, emission range from 500 to 600 nm, slit widths of
5 nm, 0.5 nm interval, 1 s response, and 1000 nm/min scan rate. The supernatant
fraction was also analyzed by 12% SDS-PAGE.
Synchronous light scattering. Synchronous light scattering was monitored using
a JASCO Spectrofluorometer FP-8200. The conditions of the spectra acquisition
were: excitation wavelength of 330 nm, emission range from 320 to 340 nm, slit
widths of 5 nm, 0.5 nm interval, 1 s response, and 1000 nm/min scan rate.
Congo Red precipitation. CR 200 μM in H2O was centrifuged before the experiment
to remove any possible precipitate. Buffer, GFP, GFP-MED15CC, or Sup35NM
aggregates were mixed 1:1 (v/v) with CR 200 μM. Samples were incubated for 1 h at
RT covered from light. Then, we centrifuged the samples for 5 min at max speed and
RT. Appearance of a red pellet was indicative of the presence of amyloid fibrils.
Circular Dichroism. CD experiments were performed using a JASCO J-715
spectropolarimeter. Measurements of the far-UV CD spectra (260–200 nm) were
made by the addition of 200 μl of 5 μM sample to a cuvette of 0.1 cm path-length.
Spectra were recorded at room temperature, 1 nm band width, and 100 nm/min
scan rate. The resulting spectrum was the average of 5 scans. The contribution of
the buffer was subtracted.
Fourier transform infrared spectroscopy. In all, 100 μl aggregated protein was
centrifuged and washed one time with H2O to remove the presence of salts. The
final pellet was resupended in 10 μl H2O. FTIR experiments were performed using
a Bruker Tensor 27 FT-IR spectrometer (Bruker Optics Inc) with a Golden Gate
MKII ATR accessory. Each spectrum consists of 32 independent scans, measured at
a spectral resolution of 4 cm−1 within 1800–1500 cm−1 range. All spectral data
were acquired and normalized using the OPUS MIR Tensor 27 software. Data was
afterwards deconvoluted using the Peak Fit 4.12 program.
Transmission electron microscopy. The morphology of the aggregated proteins
was evaluated by negative staining and using a JEOL TEM-1400Plus Transmission
Electron Microscope, 80 KV. 5 µM aggregated protein solution was diluted to 1 µM
final concentration in H2O. In total, 5 µl of the diluted solution was placed on
carbon-coated copper grids and incubated for 5 min. The grids were then washed
and stained with 5 µl of 2% w/v uranyl acetate for 1 min. Then, grids were washed
again before analysis.
Mammalian molecular cloning. MED15 CC and PP sequence were amplified by
PCR from pET21b-GFP-MED15CC/PP and assembled to pEGFP-C3 (Clontech,
plasmid #6082–1) HindIII and BamHI digested plasmid using the NEBuilder HiFi
DNA Assembly Master Mix (New England Biolabs). EGFP and EGFP-MED15CC
were amplified by PCR from pEGFP-C3 and pEGFP-C3-MED15CC, respectively, and
assembled to pTetO-FUW-OSKM (Addgene, plasmid #20321) EcoRI digested plas-
mid using the NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs).
The final vectors were transformed into XL1Blue chemically competent E. coli cells.
Mammalian cell culture. HeLa cells were grown and maintained in MEMα Glu-
tamax medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine
serum (FBS) (Thermo Fisher Scientific) at 37 °C and 5% CO2. HEK-293T were
grown and maintained in DMEM medium supplemented with 10% FBS (Gibco)
with antibiotics (penicillin/streptomycin 100 U/ml) on gelatin-coated plates at 37 °C
and 5% CO2. Laryngeal HNSCC (UT-SCC-42B) and oral HNSCC (UT-SCC-2)
were grown and maintained in DMEM medium (Thermo Fisher Scientific) sup-
plemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific) at 37 °C
and 5% CO2. Cells were passaged and plated using 1x TrypLE Express (Thermo
Fisher Scientific) or Trypsin-EDTA (0.05% Trypsin 0.53 mM EDTA•4Na) liquid
(Invitrogen).
Production of lentivirus and infection of recipient cells. Lentiviral supernatants
were produced in HEK-293T cells (5 × 106 cells per 100 mm diameter dish). Vector
transfections were performed using Fugene-6 transfection reagent (Roche)
according to the manufacturer’s protocol.
For lentiviral production, per dish, 293T cells were transfected with 3 plasmids:
(i) the ecotropic lentiviral envelope packaging plasmid pMD2.G (0.3 µg; Addgene,
plasmid #12259; containing the VsVg gene); (ii) the lentiviral packaging plasmid
pCMV-dR8.91 (3.0 µg); (from: Harvard Medical School, plasmid #516); (iii) plus
one of the following lentiviral expression constructs (3.0 µg) expressing either the
FUW-M2-rtTA vector (Addgene #20342), or, pTetO-FUW-EGFP-MED15CC or
pTetO-FUW-EGFP.
Two days later, viral supernatants (10 ml) were collected serially during the
subsequent 48 h, at 12-h intervals, each time adding fresh medium to the cells (10
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ml). The recipient 293T cells were seeded the previous day (1.5 × 105 cells per well
in a six-well plate) and each well received 1.0 ml of the corresponding lentiviral
supernatants. This procedure was repeated every 12 h for 2 days (a total of 3
additions). Recipient cells received both the FUW-M2-rtTA plus either pTetO-
FUW-EGFP-MED15CC or pTetO-FUW-EGFP.
In all, 24 h after lentiviral infection was completed; lentiviral expressing cells
were used directly. Cell samples were tested for expression of EGFP or EGFP-
MED15CC by immunofluorescence 72 h after addition of 1 μg/ml doxycycline.
Mammalian cells transfection. HeLa, laryngeal HNSCC (UT-SCC-42B) and oral
HNSCC (UT-SCC-2) cells were transfected 24 h after seeding, on eight-well glass
slides for immunofluorescence or on 10 cm dish for western blot, with 400 ng DNA
using Lipofectamine2000 (Invitrogen). After 4 h of transfection, we changed cel-
lular media to fresh one.
Immunofluorescence. Cells were fixed with 4% parafolmaldehyde (141451, Pan-
ReacAppliChem), permeabilized with 0.2% TritonX100 and blocked with 1%
bovine serum albumin (BSA) or 5% filtered FCS (Foetal Calf Serum). Primary
antibody used was against MED15 (11566–1-AP, Proteintech). For visualization,
the appropriate host-specific Alexa Fluor 555 (Thermo Fisher Scientific) secondary
antibody was used. Slides were mounted using ProLong Gold antifade reagent with
DAPI (Invitrogen). Images were captured using a Leica TCS SP5 confocal
microscope (Leica Biosystems) with a ×63 oil objective.
Soluble/insoluble fractionation. Transfected HeLa cells were trypsinized, washed
with PBS1x and resuspended in 0.5ml RIPA buffer (50mM Tris pH 7.4, 150mM
NaCl, 1% TritonX100, 2 mM EDTA, 0.5% sodium deoxycholate, and 0.1% SDS)
supplemented with protease inhibitors. After 10min incubation on ice, cells were
centrifuged for 10min at max speed and 4 °C. The supernatant corresponding to the
soluble fraction was placed in a new eppendorf tube. The pellet corresponding to the
insoluble fraction was washed with RIPA supplemented with protease inhibitors,
resuspended in 0.5 ml urea buffer (30mM Tris pH 8.5, 8M urea, 2% CHAPS) and
incubated for 20min at RT and agitation. Protein concentration of the soluble frac-
tion was measured by Bradford and 20 μg were loaded for western blot analysis. We
loaded the same volume for the insoluble fraction. Primary antibody used was against
MED15 (11566–1-AP, Proteintech), GFP (G6795, Sigma), GAPDH (AM4300, Invi-
trogen), and EEA1 (610457, BD Biosciences). The appropriate host-specific HRP
conjugated secondary antibody (BioRad) was used. Western Blot was revealed using
Immobilon® Forte Western HRP substrate (Millipore) in a VersaDoc (BioRad).
Nuclear/cytoplasmic fractionation. Nuclear and cytoplasmic fractionation was
performed with the NE-PER kit (Thermofisher #78833). In all, 10 µg protein was
loaded for western blot analyses. Primary antibody used was against MED15
(11566–1-AP, Proteintech), GFP (ab13970, Abcam), MED1 (51613, Cell signaling),
MED14 (ab72141, Abcam), MED12 (A300–774A, Bethyl Laboratoris), H3K9me3
(2118 s, Cell Signaling), and LaminA/C (sc-6215 (N-18) or sc-376248 (E-1), Santa
Cruz Biotechnology).
Statistics and reproducibility. Statistical analyses were performed using Graph-
Pad Prism v8 or SigmaPlot v10. Unless otherwise indicated data are shown as the
mean ± standard deviation (SD). In Fig. 6C the data correspond to the mean ± SEM
and significance in difference between two groups were tested by Student t test.
Triplicate samples were analyzed per experiment.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The unprocessed immunoblotting images are shown in Supplementary Fig. 11. The
source data behind the graphs are provided in Supplementary Data 3. All datasets in the
current study are available from the corresponding author on reasonable requests.
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